Anemia and transfusion requirements among Ugandan children with severe malaria treated with intravenous artesunate

Michael T. Hawkes; Robert Opoka; Andrea L. Conroy; Robyn E. Elphinstone; Heather A. Hume; Sophie Namasopo; Kevin C. Kain

doi:10.1080/08880018.2019.1701161

Anemia and transfusion requirements among Ugandan children with severe malaria treated with intravenous artesunate

Michael T. Hawkes, Robert Opoka, Andrea L. Conroy, Robyn E. Elphinstone, Heather A. Hume, Sophie Namasopo, Kevin C. Kain

Medical College, East Africa

Research output: Contribution to journal › Article

4 Citations (Scopus)

Abstract

Parenteral artesunate for the treatment of severe malaria in non-immune travelers is associated with late-onset hemolysis. In children in sub-Saharan Africa, the hematologic effects of malaria and artesunate are less well documented. Here we report a prospective case series of 91 children with severe malaria treated with parenteral artesunate, managed at a resource-poor hospital in Africa, with longitudinal data on hemoglobin (Hb), lactate dehydrogenase (LDH), haptoglobin, and erythrocyte morphology. The median (range) age was 2 (1–8) years and 43 (47%) were female. The median (IQR) admission Hb level was 69 (55–78) g/L and 20 patients (22%) had severe malarial anemia (Hb

Original language	Undefined/Unknown
Journal	Paediatrics and Child Health, East Africa
DOIs	https://doi.org/10.1080/08880018.2019.1701161
Publication status	Published - 1 Dec 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/08880018.2019.1701161Licence: Unspecified

http://ecommons.aku.edu/eastafrica_fhs_mc_paediatr_child_health/365

Cite this

@article{afc6ce1c511343b4aa2a38a416dfb3af,

title = "Anemia and transfusion requirements among Ugandan children with severe malaria treated with intravenous artesunate",

abstract = "Parenteral artesunate for the treatment of severe malaria in non-immune travelers is associated with late-onset hemolysis. In children in sub-Saharan Africa, the hematologic effects of malaria and artesunate are less well documented. Here we report a prospective case series of 91 children with severe malaria treated with parenteral artesunate, managed at a resource-poor hospital in Africa, with longitudinal data on hemoglobin (Hb), lactate dehydrogenase (LDH), haptoglobin, and erythrocyte morphology. The median (range) age was 2 (1–8) years and 43 (47%) were female. The median (IQR) admission Hb level was 69 (55–78) g/L and 20 patients (22%) had severe malarial anemia (Hb ",

author = "Hawkes, {Michael T.} and Robert Opoka and Conroy, {Andrea L.} and Elphinstone, {Robyn E.} and Hume, {Heather A.} and Sophie Namasopo and Kain, {Kevin C.}",

year = "2019",

month = dec,

day = "1",

doi = "10.1080/08880018.2019.1701161",

language = "Undefined/Unknown",

journal = "Paediatrics and Child Health, East Africa",

}

TY - JOUR

T1 - Anemia and transfusion requirements among Ugandan children with severe malaria treated with intravenous artesunate

AU - Hawkes, Michael T.

AU - Opoka, Robert

AU - Conroy, Andrea L.

AU - Elphinstone, Robyn E.

AU - Hume, Heather A.

AU - Namasopo, Sophie

AU - Kain, Kevin C.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Parenteral artesunate for the treatment of severe malaria in non-immune travelers is associated with late-onset hemolysis. In children in sub-Saharan Africa, the hematologic effects of malaria and artesunate are less well documented. Here we report a prospective case series of 91 children with severe malaria treated with parenteral artesunate, managed at a resource-poor hospital in Africa, with longitudinal data on hemoglobin (Hb), lactate dehydrogenase (LDH), haptoglobin, and erythrocyte morphology. The median (range) age was 2 (1–8) years and 43 (47%) were female. The median (IQR) admission Hb level was 69 (55–78) g/L and 20 patients (22%) had severe malarial anemia (Hb

AB - Parenteral artesunate for the treatment of severe malaria in non-immune travelers is associated with late-onset hemolysis. In children in sub-Saharan Africa, the hematologic effects of malaria and artesunate are less well documented. Here we report a prospective case series of 91 children with severe malaria treated with parenteral artesunate, managed at a resource-poor hospital in Africa, with longitudinal data on hemoglobin (Hb), lactate dehydrogenase (LDH), haptoglobin, and erythrocyte morphology. The median (range) age was 2 (1–8) years and 43 (47%) were female. The median (IQR) admission Hb level was 69 (55–78) g/L and 20 patients (22%) had severe malarial anemia (Hb

U2 - 10.1080/08880018.2019.1701161

DO - 10.1080/08880018.2019.1701161

M3 - Article

JO - Paediatrics and Child Health, East Africa

JF - Paediatrics and Child Health, East Africa

ER -